{
    "hands_on_practices": [
        {
            "introduction": "A fundamental step in validating a companion diagnostic is to quantify its intrinsic ability to discriminate between patient populations, such as those who will respond to a therapy and those who will not. This exercise asks you to derive the Area Under the Receiver Operating Characteristic Curve (AUC) from first principles, a cornerstone metric of clinical validity, using a common statistical model. By working through this derivation , you will gain a deeper understanding of how a diagnostic's performance is fundamentally measured.",
            "id": "4542008",
            "problem": "A targeted oncology therapy requires a companion diagnostic to establish clinical validity for enriching patients likely to respond. A continuous biomarker score $S$ is produced by the companion diagnostic for each patient prior to treatment initiation. In a pivotal trial used to assess clinical validity, the binary clinical outcome $Y$ is defined as responder ($Y=1$) versus non-responder ($Y=0$). Under a large-sample regime and stable assay performance, it is reasonable to model the conditional distributions\n$$\nS \\mid Y=1 \\sim \\mathcal{N}(\\mu_{1}, \\sigma_{1}^{2}), \\quad S \\mid Y=0 \\sim \\mathcal{N}(\\mu_{0}, \\sigma_{0}^{2}),\n$$\nwith independent draws across patients and independence between draws from the two groups. The test positivity rule is that a patient is classified as positive for treatment if $S \\geq c$ for a threshold $c \\in \\mathbb{R}$.\n\nStarting only from the core definitions of sensitivity, specificity, and the Receiver Operating Characteristic (ROC) curve, derive an analytical expression for the area under the ROC curve (AUC) implied by the model above, expressed in terms of $\\mu_{1}, \\mu_{0}, \\sigma_{1}, \\sigma_{0}$. Then, using the parameter values $\\mu_{1}=2.0$, $\\sigma_{1}=0.6$, $\\mu_{0}=1.0$, and $\\sigma_{0}=0.5$, compute the numerical value of the AUC. Express the final AUC as a unitless number and round your answer to four significant figures.",
            "solution": "The problem requires the derivation of an analytical expression for the area under the Receiver Operating Characteristic (ROC) curve (AUC) for a specific probabilistic model and the subsequent computation of its numerical value.\n\nFirst, we establish the fundamental definitions based on the problem statement. A continuous biomarker score $S$ is modeled with conditional normal distributions based on the binary clinical outcome $Y$, where $Y=1$ indicates a responder and $Y=0$ indicates a non-responder.\n$$\nS \\mid Y=1 \\sim \\mathcal{N}(\\mu_{1}, \\sigma_{1}^{2})\n$$\n$$\nS \\mid Y=0 \\sim \\mathcal{N}(\\mu_{0}, \\sigma_{0}^{2})\n$$\nA test is considered positive if a patient's score $S$ is at or above a given threshold $c \\in \\mathbb{R}$, i.e., $S \\ge c$.\n\nThe performance of this diagnostic test at a threshold $c$ is quantified by its sensitivity and specificity. Sensitivity, also known as the True Positive Rate (TPR), is the probability that a responder is correctly classified as positive.\n$$\n\\text{TPR}(c) = P(S \\ge c \\mid Y=1)\n$$\nSpecificity is the probability that a non-responder is correctly classified as negative.\n$$\n\\text{Specificity}(c) = P(S < c \\mid Y=0)\n$$\nThe False Positive Rate (FPR) is defined as $1 - \\text{Specificity}$, which is the probability that a non-responder is incorrectly classified as positive.\n$$\n\\text{FPR}(c) = 1 - P(S < c \\mid Y=0) = P(S \\ge c \\mid Y=0)\n$$\nThe ROC curve is the parametric plot of $\\text{TPR}(c)$ versus $\\text{FPR}(c)$ as the threshold $c$ is varied over all possible real values. The AUC is the area under this curve.\n\nA fundamental and elegant result from statistical theory states that the AUC is equivalent to the probability that a randomly chosen individual from the positive group (responders, $Y=1$) will have a higher score than a randomly chosen individual from the negative group (non-responders, $Y=0$). Let $S_1$ denote the score for a random responder and $S_0$ denote the score for a random non-responder. Then, based on the problem's setup, $S_1 \\sim \\mathcal{N}(\\mu_{1}, \\sigma_{1}^{2})$ and $S_0 \\sim \\mathcal{N}(\\mu_{0}, \\sigma_{0}^{2})$, and they are independent. The AUC can thus be expressed as:\n$$\n\\text{AUC} = P(S_1 > S_0)\n$$\nThis identity can be rigorously shown by integrating the ROC curve. The AUC is $\\int_0^1 \\text{TPR} \\,d(\\text{FPR})$. Making a change of variables to the threshold $c$, and noting that as $c$ varies from $-\\infty$ to $+\\infty$, the FPR varies from $1$ to $0$:\n$$\n\\text{AUC} = \\int_{\\text{FPR}=1}^{\\text{FPR}=0} \\text{TPR}(c) \\, d(\\text{FPR}(c)) = \\int_{-\\infty}^{\\infty} \\text{TPR}(c) \\left(-\\frac{d(\\text{FPR}(c))}{dc}\\right) dc\n$$\nWith $\\text{FPR}(c) = \\int_c^\\infty f_0(s)ds$, where $f_0$ is the PDF of $S \\mid Y=0$, we have $-\\frac{d(\\text{FPR}(c))}{dc} = f_0(c)$. So,\n$$\n\\text{AUC} = \\int_{-\\infty}^{\\infty} P(S_1 \\ge c) f_0(c) dc = P(S_1 > S_0)\n$$\nTo calculate this probability, we define a new random variable $D = S_1 - S_0$. Since $S_1$ and $S_0$ are independent normal random variables, their difference $D$ is also normally distributed.\nThe mean of $D$ is the difference of the means:\n$$\nE[D] = E[S_1] - E[S_0] = \\mu_{1} - \\mu_{0}\n$$\nThe variance of $D$, due to the independence of $S_1$ and $S_0$, is the sum of the variances:\n$$\n\\text{Var}(D) = \\text{Var}(S_1 - S_0) = \\text{Var}(S_1) + (-1)^{2}\\text{Var}(S_0) = \\sigma_{1}^{2} + \\sigma_{0}^{2}\n$$\nThus, the distribution of the difference is $D \\sim \\mathcal{N}(\\mu_{1} - \\mu_{0}, \\sigma_{1}^{2} + \\sigma_{0}^{2})$.\n\nThe AUC is the probability $P(D > 0)$. To find this probability, we standardize the random variable $D$ to a standard normal variable $Z \\sim \\mathcal{N}(0, 1)$:\n$$\nZ = \\frac{D - E[D]}{\\sqrt{\\text{Var}(D)}} = \\frac{D - (\\mu_{1} - \\mu_{0})}{\\sqrt{\\sigma_{1}^{2} + \\sigma_{0}^{2}}}\n$$\nThe inequality $D > 0$ can be rewritten in terms of $Z$:\n$$\nZ > \\frac{0 - (\\mu_{1} - \\mu_{0})}{\\sqrt{\\sigma_{1}^{2} + \\sigma_{0}^{2}}} \\implies Z > -\\frac{\\mu_{1} - \\mu_{0}}{\\sqrt{\\sigma_{1}^{2} + \\sigma_{0}^{2}}}\n$$\nLet $\\Phi(z)$ denote the cumulative distribution function (CDF) of the standard normal distribution, $\\Phi(z) = P(Z \\le z)$. Using the property $P(Z > a) = 1 - \\Phi(a)$ and the symmetry property $\\Phi(-a) = 1 - \\Phi(a)$, it follows that $P(Z > -a) = \\Phi(a)$.\nTherefore, the AUC is:\n$$\n\\text{AUC} = P\\left(Z > -\\frac{\\mu_{1} - \\mu_{0}}{\\sqrt{\\sigma_{1}^{2} + \\sigma_{0}^{2}}}\\right) = \\Phi\\left(\\frac{\\mu_{1} - \\mu_{0}}{\\sqrt{\\sigma_{1}^{2} + \\sigma_{0}^{2}}}\\right)\n$$\nThis is the required analytical expression for the AUC in terms of the model parameters.\n\nNext, we substitute the given numerical values: $\\mu_{1}=2.0$, $\\sigma_{1}=0.6$, $\\mu_{0}=1.0$, and $\\sigma_{0}=0.5$.\nThe argument of the CDF $\\Phi$ is calculated as:\n$$\n\\frac{\\mu_{1} - \\mu_{0}}{\\sqrt{\\sigma_{1}^{2} + \\sigma_{0}^{2}}} = \\frac{2.0 - 1.0}{\\sqrt{(0.6)^{2} + (0.5)^{2}}} = \\frac{1.0}{\\sqrt{0.36 + 0.25}} = \\frac{1.0}{\\sqrt{0.61}}\n$$\nWe compute the numerical value of this argument:\n$$\n\\frac{1.0}{\\sqrt{0.61}} \\approx \\frac{1.0}{0.78102497} \\approx 1.28037\n$$\nFinally, we evaluate the standard normal CDF at this value:\n$$\n\\text{AUC} = \\Phi(1.28037) \\approx 0.899797\n$$\nRounding this result to four significant figures, as requested, gives $0.8998$.",
            "answer": "$$\n\\boxed{0.8998}\n$$"
        },
        {
            "introduction": "While a companion diagnostic's intrinsic performance is key, its real-world impact depends on how it is used in a clinical context, where misclassification is inevitable. This practice explores how an imperfect diagnostic used for patient selection in a clinical trial can lead to a dilution of the observed treatment effect. You will use Bayes' theorem to model this hypothetical scenario , providing critical insight into the interpretation of pivotal trial results for targeted therapies.",
            "id": "4541995",
            "problem": "A Phase III randomized controlled trial evaluates a targeted kinase inhibitor that is hypothesized to reduce the 12-month progression risk only in patients harboring a specific oncogenic mutation. A Companion Diagnostic (CDx) is used to enroll patients who test positive for the mutation. The CDx is imperfect, inducing misclassification. Assume the following scientifically grounded quantities and relationships.\n\nFundamental base and core definitions to employ:\n- Bayes' theorem: for events $A$ and $B$ with $\\Pr(B) \\neq 0$, $\\Pr(A \\mid B) = \\frac{\\Pr(B \\mid A)\\Pr(A)}{\\Pr(B)}$.\n- Diagnostic sensitivity and specificity: sensitivity $\\mathrm{Se}$ is $\\Pr(\\text{test positive} \\mid \\text{truly biomarker-positive})$, specificity $\\mathrm{Sp}$ is $\\Pr(\\text{test negative} \\mid \\text{truly biomarker-negative})$.\n- Positive Predictive Value (PPV): $\\Pr(\\text{truly biomarker-positive} \\mid \\text{test positive})$.\n- Relative Risk (RR): for a treatment versus a control, $\\mathrm{RR} = \\frac{\\text{risk under treatment}}{\\text{risk under control}}$.\n\nTrial design and parameters:\n- The true biomarker prevalence in the screened population is $p = 0.3$.\n- The CDx sensitivity is $\\mathrm{Se} = 0.85$ and the specificity is $\\mathrm{Sp} = 0.90$.\n- Among truly biomarker-positive patients, the 12-month progression risk under control is $r_{1} = 0.35$.\n- Among truly biomarker-negative patients, the 12-month progression risk under control is $r_{0} = 0.12$.\n- The kinase inhibitor acts only in truly biomarker-positive patients, yielding a constant multiplicative effect on risk with treatment relative risk $\\mathrm{RR}_{t} = 0.55$ in that subgroup; there is no effect in truly biomarker-negative patients (relative risk equals $1$ in that subgroup).\n- Patients who test CDx-positive are randomized 1:1 to treatment or control; risk is evaluated over 12 months.\n\nStarting from Bayes' theorem and the definitions of sensitivity, specificity, Positive Predictive Value, and Relative Risk, derive a closed-form expression for the observed Relative Risk within the CDx-positive stratum, $\\mathrm{RR}_{\\text{obs}}$, that accounts for the composition of truly biomarker-positive and false-positive patients induced by the imperfect CDx. Then, using the numerical parameter values above, compute the numerical value of $\\mathrm{RR}_{\\text{obs}}$. Express your answer as a dimensionless ratio and round to four significant figures.",
            "solution": "The objective is to derive a closed-form expression for the observed Relative Risk, $\\mathrm{RR}_{\\text{obs}}$, in the stratum of patients who test positive with the Companion Diagnostic (CDx), and then to compute its numerical value.\n\nLet us define the following events:\n- $M^{+}$: The event that a patient is truly biomarker-positive.\n- $M^{-}$: The event that a patient is truly biomarker-negative.\n- $T^{+}$: The event that a patient tests positive with the CDx.\n- $T^{-}$: The event that a patient tests negative with the CDx.\n- $D$: The event that a patient experiences disease progression within $12$ months.\n- $\\text{Tr}$: The event that a patient is randomized to the treatment arm.\n- $C$: The event that a patient is randomized to the control arm.\n\nThe problem provides the following parameters:\n- True biomarker prevalence: $\\Pr(M^{+}) = p = 0.3$. Consequently, $\\Pr(M^{-}) = 1 - p = 0.7$.\n- CDx sensitivity: $\\mathrm{Se} = \\Pr(T^{+} \\mid M^{+}) = 0.85$.\n- CDx specificity: $\\mathrm{Sp} = \\Pr(T^{-} \\mid M^{-}) = 0.90$. From this, we can deduce the false positive rate: $\\Pr(T^{+} \\mid M^{-}) = 1 - \\mathrm{Sp} = 1 - 0.90 = 0.10$.\n- Risk in truly positive patients on control: $r_{1} = \\Pr(D \\mid M^{+}, C) = 0.35$.\n- Risk in truly negative patients on control: $r_{0} = \\Pr(D \\mid M^{-}, C) = 0.12$.\n- Relative risk of treatment in truly positive patients: $\\mathrm{RR}_{t} = \\frac{\\Pr(D \\mid M^{+}, \\text{Tr})}{\\Pr(D \\mid M^{+}, C)} = 0.55$.\n- Relative risk of treatment in truly negative patients: $\\frac{\\Pr(D \\mid M^{-}, \\text{Tr})}{\\Pr(D \\mid M^{-}, C)} = 1$.\n\nThe observed Relative Risk, $\\mathrm{RR}_{\\text{obs}}$, is the ratio of progression risk in the treatment arm to the progression risk in the control arm, conditioned on patients being in the CDx-positive stratum ($T^{+}$).\n$$\n\\mathrm{RR}_{\\text{obs}} = \\frac{\\Pr(D \\mid T^{+}, \\text{Tr})}{\\Pr(D \\mid T^{+}, C)}\n$$\n\nFirst, we must characterize the composition of the CDx-positive ($T^{+}$) population. This population is a mixture of truly biomarker-positive patients (true positives) and truly biomarker-negative patients (false positives). The proportion of true positives among those who test positive is the Positive Predictive Value (PPV), denoted here as $\\pi_{\\text{PPV}}$.\n$$\n\\pi_{\\text{PPV}} = \\Pr(M^{+} \\mid T^{+})\n$$\nUsing Bayes' theorem and the law of total probability, we can express $\\pi_{\\text{PPV}}$ in terms of the given parameters. The denominator, $\\Pr(T^{+})$, is calculated as:\n$$\n\\Pr(T^{+}) = \\Pr(T^{+} \\mid M^{+})\\Pr(M^{+}) + \\Pr(T^{+} \\mid M^{-})\\Pr(M^{-})\n$$\nSubstituting the given definitions:\n$$\n\\Pr(T^{+}) = \\mathrm{Se} \\cdot p + (1 - \\mathrm{Sp}) \\cdot (1 - p)\n$$\nThe PPV is then:\n$$\n\\pi_{\\text{PPV}} = \\Pr(M^{+} \\mid T^{+}) = \\frac{\\Pr(T^{+} \\mid M^{+})\\Pr(M^{+})}{\\Pr(T^{+})} = \\frac{\\mathrm{Se} \\cdot p}{\\mathrm{Se} \\cdot p + (1 - \\mathrm{Sp})(1 - p)}\n$$\nThe proportion of false positives in the CDx-positive group is $\\Pr(M^{-} \\mid T^{+}) = 1 - \\pi_{\\text{PPV}}$.\n\nNext, we derive the expression for the observed risk in the control arm, $R_{\\text{control, obs}} = \\Pr(D \\mid T^{+}, C)$. This is a weighted average of the risks for the true-positive and false-positive subgroups, where the weights are their respective proportions within the $T^{+}$ cohort.\n$$\nR_{\\text{control, obs}} = \\Pr(D \\mid M^{+}, C)\\Pr(M^{+} \\mid T^{+}) + \\Pr(D \\mid M^{-}, C)\\Pr(M^{-} \\mid T^{+})\n$$\nSubstituting the defined terms:\n$$\nR_{\\text{control, obs}} = r_{1} \\cdot \\pi_{\\text{PPV}} + r_{0} \\cdot (1 - \\pi_{\\text{PPV}})\n$$\n\nSimilarly, we derive the expression for the observed risk in the treatment arm, $R_{\\text{treat, obs}} = \\Pr(D \\mid T^{+}, \\text{Tr})$.\nThe risk for a truly positive patient on treatment is $\\Pr(D \\mid M^{+}, \\text{Tr}) = \\mathrm{RR}_{t} \\cdot \\Pr(D \\mid M^{+}, C) = \\mathrm{RR}_{t} \\cdot r_{1}$.\nThe risk for a truly negative patient on treatment is $\\Pr(D \\mid M^{-}, \\text{Tr}) = 1 \\cdot \\Pr(D \\mid M^{-}, C) = r_{0}$.\nThe observed risk in the treatment arm is the weighted average:\n$$\nR_{\\text{treat, obs}} = \\Pr(D \\mid M^{+}, \\text{Tr})\\Pr(M^{+} \\mid T^{+}) + \\Pr(D \\mid M^{-}, \\text{Tr})\\Pr(M^{-} \\mid T^{+})\n$$\nSubstituting the defined terms:\n$$\nR_{\\text{treat, obs}} = (\\mathrm{RR}_{t} \\cdot r_{1}) \\cdot \\pi_{\\text{PPV}} + r_{0} \\cdot (1 - \\pi_{\\text{PPV}})\n$$\n\nFinally, we can write the closed-form expression for the observed Relative Risk, $\\mathrm{RR}_{\\text{obs}}$:\n$$\n\\mathrm{RR}_{\\text{obs}} = \\frac{R_{\\text{treat, obs}}}{R_{\\text{control, obs}}} = \\frac{(\\mathrm{RR}_{t} \\cdot r_{1}) \\cdot \\pi_{\\text{PPV}} + r_{0} \\cdot (1 - \\pi_{\\text{PPV}})}{r_{1} \\cdot \\pi_{\\text{PPV}} + r_{0} \\cdot (1 - \\pi_{\\text{PPV}})}\n$$\nSubstituting the expression for $\\pi_{\\text{PPV}}$ yields the full closed-form expression in terms of the fundamental parameters:\n$$\n\\mathrm{RR}_{\\text{obs}} = \\frac{(\\mathrm{RR}_{t} \\cdot r_{1}) \\left(\\frac{\\mathrm{Se} \\cdot p}{\\mathrm{Se} \\cdot p + (1 - \\mathrm{Sp})(1 - p)}\\right) + r_{0} \\left(1 - \\frac{\\mathrm{Se} \\cdot p}{\\mathrm{Se} \\cdot p + (1 - \\mathrm{Sp})(1 - p)}\\right)}{r_{1} \\left(\\frac{\\mathrm{Se} \\cdot p}{\\mathrm{Se} \\cdot p + (1 - \\mathrm{Sp})(1 - p)}\\right) + r_{0} \\left(1 - \\frac{\\mathrm{Se} \\cdot p}{\\mathrm{Se} \\cdot p + (1 - \\mathrm{Sp})(1 - p)}\\right)}\n$$\nThis is the required closed-form expression.\n\nNow, we compute the numerical value using the provided parameters:\n$p = 0.3$, $\\mathrm{Se} = 0.85$, $\\mathrm{Sp} = 0.90$, $r_{1} = 0.35$, $r_{0} = 0.12$, $\\mathrm{RR}_{t} = 0.55$.\n\n1.  Calculate the probability of a positive test, $\\Pr(T^{+})$:\n    $$\n    \\Pr(T^{+}) = (0.85)(0.3) + (1 - 0.90)(1 - 0.3) = 0.255 + (0.10)(0.7) = 0.255 + 0.070 = 0.325\n    $$\n\n2.  Calculate the Positive Predictive Value, $\\pi_{\\text{PPV}}$:\n    $$\n    \\pi_{\\text{PPV}} = \\Pr(M^{+} \\mid T^{+}) = \\frac{\\Pr(T^{+} \\mid M^{+})\\Pr(M^{+})}{\\Pr(T^{+})} = \\frac{0.255}{0.325} = \\frac{51}{65}\n    $$\n    Thus, the proportion of false positives is $1 - \\pi_{\\text{PPV}} = 1 - \\frac{51}{65} = \\frac{14}{65}$.\n\n3.  Calculate the observed risk in the control arm ($R_{\\text{control, obs}}$):\n    $$\n    R_{\\text{control, obs}} = r_{1} \\cdot \\pi_{\\text{PPV}} + r_{0} \\cdot (1 - \\pi_{\\text{PPV}}) = (0.35)\\left(\\frac{51}{65}\\right) + (0.12)\\left(\\frac{14}{65}\\right)\n    $$\n    $$\n    R_{\\text{control, obs}} = \\frac{(0.35)(51) + (0.12)(14)}{65} = \\frac{17.85 + 1.68}{65} = \\frac{19.53}{65} \\approx 0.30046\n    $$\n\n4.  Calculate the observed risk in the treatment arm ($R_{\\text{treat, obs}}$):\n    $$\n    R_{\\text{treat, obs}} = (\\mathrm{RR}_{t} \\cdot r_{1}) \\cdot \\pi_{\\text{PPV}} + r_{0} \\cdot (1 - \\pi_{\\text{PPV}}) = ((0.55)(0.35))\\left(\\frac{51}{65}\\right) + (0.12)\\left(\\frac{14}{65}\\right)\n    $$\n    $$\n    R_{\\text{treat, obs}} = \\frac{(0.55)(0.35)(51) + (0.12)(14)}{65} = \\frac{(0.1925)(51) + 1.68}{65} = \\frac{9.8175 + 1.68}{65} = \\frac{11.4975}{65} \\approx 0.17688\n    $$\n\n5.  Calculate the observed Relative Risk ($\\mathrm{RR}_{\\text{obs}}$):\n    $$\n    \\mathrm{RR}_{\\text{obs}} = \\frac{R_{\\text{treat, obs}}}{R_{\\text{control, obs}}} = \\frac{11.4975/65}{19.53/65} = \\frac{11.4975}{19.53} \\approx 0.5886994367...\n    $$\nRounding to four significant figures, the observed Relative Risk is $0.5887$. This value is greater than the true relative risk in the biomarker-positive subgroup ($\\mathrm{RR}_{t} = 0.55$) due to the inclusion of false-positive patients who do not benefit from the treatment, thus diluting the observed treatment effect.",
            "answer": "$$\n\\boxed{0.5887}\n$$"
        },
        {
            "introduction": "The lifecycle of a companion diagnostic extends far beyond its initial approval, often involving manufacturing changes that require rigorous evaluation to ensure continued patient benefit. This advanced exercise introduces a health economic framework using Quality-Adjusted Life Years (QALYs) to quantify the net clinical utility of a diagnostic test. By calculating the change in QALYs resulting from a hypothetical modification to a CDx , you will learn how to connect shifts in diagnostic accuracy to tangible patient outcomes.",
            "id": "4541998",
            "problem": "A targeted oncology therapy is approved with a Companion Diagnostic (CDx) that identifies a biomarker-positive subgroup expected to benefit from treatment. Clinical practice treats only those patients who test positive on the CDx. A manufacturing change control introduces a reagent change that necessitates a bridging study to verify performance comparability. The reference truth for biomarker status is a well-validated orthogonal assay. The following quantities are defined according to standard diagnostic performance metrics and are assumed constant across the intended use population:\n\n- Sensitivity is the probability of a positive test given truly biomarker-positive status.\n- Specificity is the probability of a negative test given truly biomarker-negative status.\n- Prevalence is the probability that a randomly selected patient from the tested population is truly biomarker-positive.\n\nLet the original CDx have sensitivity $S_{o} = 0.95$ and specificity $C_{o} = 0.97$. In a bridging study performed after the reagent change, the new CDx exhibits sensitivity $S_{n} = 0.93$ and specificity $C_{n} = 0.985$. The biomarker prevalence in the clinical testing population is $p = 0.15$.\n\nClinical pharmacology modeling for benefit-risk quantification uses the Quality-Adjusted Life Year (QALY). Assume:\n- A correctly treated biomarker-positive patient accrues an average incremental benefit of $B = 0.60$ QALY relative to not receiving the therapy.\n- A treated biomarker-negative patient accrues an average incremental harm of $H = -0.05$ QALY due to adverse effects and costs, relative to not receiving the therapy.\n- Patients testing negative are not treated; thus, they accrue $0$ QALY under this decision policy relative to the no-treatment baseline.\n\nStarting only from the definitions of sensitivity, specificity, prevalence, Bayesâ€™ theorem for conditional probabilities, and the law of total expectation, derive an expression for the expected net QALY per patient attributable to using a CDx under the treat-positive policy. Then, compute the expected change in total QALYs per $1000$ tested patients when switching from the original CDx to the new CDx (new minus original). Express your final result in QALYs per $1000$ tested patients and round your answer to four significant figures.",
            "solution": "The first task is to derive an expression for the expected net QALY per patient. Let us define the following events:\n- $M^+$: The event that a patient is truly biomarker-positive.\n- $M^-$: The event that a patient is truly biomarker-negative.\n- $T^+$: The event that the CDx test result is positive.\n- $T^-$: The event that the CDx test result is negative.\n\nFrom the problem statement, we have the following probabilities for a generic CDx with sensitivity $S$ and specificity $C$:\n- $P(M^+) = p$\n- $P(M^-) = 1 - p$\n- $P(T^+ | M^+) = S$ (Sensitivity)\n- $P(T^- | M^+) = 1 - S$ (False Negative Rate)\n- $P(T^- | M^-) = C$ (Specificity)\n- $P(T^+ | M^-) = 1 - C$ (False Positive Rate)\n\nLet $Q$ be the random variable representing the incremental QALY gain for a randomly selected patient. The value of $Q$ depends on the test outcome and the true biomarker status.\n- If a patient tests positive ($T^+$) and is truly positive ($M^+$), they are correctly treated, and the QALY gain is $B$.\n- If a patient tests positive ($T^+$) and is truly negative ($M^-$), they are incorrectly treated, and the QALY gain (harm) is $H$.\n- If a patient tests negative ($T^-$), they are not treated, and the QALY gain is $0$, regardless of their true biomarker status.\n\nWe can calculate the expected value of $Q$, denoted $E[Q]$, using the law of total expectation, by conditioning on the true biomarker status of the patient.\n$$E[Q] = E[Q | M^+] P(M^+) + E[Q | M^-] P(M^-)$$\n\nFirst, we find the expected QALY for a truly biomarker-positive patient, $E[Q | M^+]$. Such a patient can test positive with probability $P(T^+|M^+) = S$ or test negative with probability $P(T^-|M^+) = 1-S$.\n- If they test positive, they are treated, and gain $B$ QALYs.\n- If they test negative, they are not treated, and gain $0$ QALYs.\nTherefore, the expected QALY for a biomarker-positive patient is:\n$$E[Q | M^+] = B \\cdot P(T^+ | M^+) + 0 \\cdot P(T^- | M^+) = B \\cdot S$$\n\nNext, we find the expected QALY for a truly biomarker-negative patient, $E[Q | M^-]$. Such a patient can test positive with probability $P(T^+|M^-) = 1-C$ or test negative with probability $P(T^-|M^-) = C$.\n- If they test positive, they are treated, and gain $H$ QALYs.\n- If they test negative, they are not treated, and gain $0$ QALYs.\nTherefore, the expected QALY for a biomarker-negative patient is:\n$$E[Q | M^-] = H \\cdot P(T^+ | M^-) + 0 \\cdot P(T^- | M^-) = H \\cdot (1 - C)$$\n\nSubstituting these conditional expectations into the law of total expectation formula:\n$$E[Q] = (B \\cdot S) \\cdot P(M^+) + (H \\cdot (1 - C)) \\cdot P(M^-)$$\n$$E[Q] = B \\cdot S \\cdot p + H \\cdot (1 - C) \\cdot (1 - p)$$\nThis is the required general expression for the expected net QALY per patient attributable to using the CDx under the treat-positive policy.\n\nThe second task is to compute the expected change in total QALYs per $1000$ tested patients when switching from the original CDx to the new CDx.\nLet $E[Q_o]$ and $E[Q_n]$ be the expected QALY per patient for the original and new CDx, respectively. Using the derived formula:\n$$E[Q_o] = B \\cdot S_o \\cdot p + H \\cdot (1 - C_o) \\cdot (1 - p)$$\n$$E[Q_n] = B \\cdot S_n \\cdot p + H \\cdot (1 - C_n) \\cdot (1 - p)$$\n\nThe change in expected QALY per patient, $\\Delta E[Q]$, is $E[Q_n] - E[Q_o]$:\n$$\\Delta E[Q] = (B \\cdot S_n \\cdot p + H \\cdot (1 - C_n) \\cdot (1 - p)) - (B \\cdot S_o \\cdot p + H \\cdot (1 - C_o) \\cdot (1 - p))$$\n$$\\Delta E[Q] = B \\cdot p \\cdot (S_n - S_o) + H \\cdot (1 - p) \\cdot [(1 - C_n) - (1 - C_o)]$$\n$$\\Delta E[Q] = B \\cdot p \\cdot (S_n - S_o) + H \\cdot (1 - p) \\cdot (C_o - C_n)$$\n\nNow, we substitute the given numerical values:\n$p = 0.15$\n$B = 0.60$\n$H = -0.05$\n$S_o = 0.95$\n$C_o = 0.97$\n$S_n = 0.93$\n$C_n = 0.985$\n\nFirst, calculate the differences in performance:\n$S_n - S_o = 0.93 - 0.95 = -0.02$\n$C_o - C_n = 0.97 - 0.985 = -0.015$\n\nSubstitute these into the expression for $\\Delta E[Q]$:\n$$\\Delta E[Q] = (0.60)(0.15)(-0.02) + (-0.05)(1 - 0.15)(-0.015)$$\n$$\\Delta E[Q] = (0.09)(-0.02) + (-0.05)(0.85)(-0.015)$$\n$$\\Delta E[Q] = -0.0018 + (-0.0425)(-0.015)$$\n$$\\Delta E[Q] = -0.0018 + 0.0006375$$\n$$\\Delta E[Q] = -0.0011625 \\text{ QALY per patient}$$\n\nThe problem asks for the expected change in total QALYs per $1000$ tested patients. Let this be $\\Delta Q_{1000}$.\n$$\\Delta Q_{1000} = 1000 \\times \\Delta E[Q]$$\n$$\\Delta Q_{1000} = 1000 \\times (-0.0011625)$$\n$$\\Delta Q_{1000} = -1.1625$$\n\nThe final step is to round the result to four significant figures.\n$$-1.1625 \\approx -1.163$$\nThe expected change is a loss of approximately $1.163$ QALYs per $1000$ patients tested.",
            "answer": "$$\\boxed{-1.163}$$"
        }
    ]
}